1. Analyst View
2. Global Proteins Therapeutic Market
2.1 Market Analysis
2.1.1 Market Size
2.1.2 Proteins Therapeutic Market vs Pharmaceutical Market
2.1.3 Market Segmentation
2.2 Future Outlook (2010-2012)
3. Industry Performance
3.1 Monoclonal Antibodies (mAb)
3.1.1 Market Size
3.1.2 By Application
3.1.3 Key Geographical Markets
3.1.4 Key Players and Drugs
3.1.5 Industry Analysis
3.1.6 Future Outlook (2010-2012)
3.2 Erythropoietin (EPO)
3.2.1 Market Size
3.2.2 By Application
3.2.3 Key Geographical Markets
3.2.4 Key Players and Drugs
3.2.5 Industry Analysis
3.2.6 Future Outlook (2010-2012)
3.3 Insulin
3.3.1 Market Size
3.3.2 By Application
3.3.3 Key Geographical Markets
3.3.4 Key Players and Drugs
3.3.5 Industry Analysis
3.3.6 Future Outlook (2010-2012)
3.4 Interferon (IFN)
3.4.1 Market Size
3.4.2 Key Geographical Markets
3.4.3 Key Players and Drugs
3.4.4 Industry Analysis
3.4.5 Future Outlook (2010-2012)
3.5 Human Growth Hormone (HGH)
3.5.1 Market Size
3.5.2 By Application
3.5.3 Key Geographical Markets
3.5.4 Key Players and Drugs
3.5.5 Industry Analysis
3.5.6 Future Outlook (2010-2012)
3.6 Blood Clotting Factor
3.6.1 Market Size
3.6.2 Key Players and Drugs
3.6.3 Industry Analysis
3.6.4 Future Outlook (2010-2012)
3.7 Follicle Stimulating Hormone (FSH)
3.7.1 Market Size
3.7.2 Key Players and Drugs
3.7.3 Industry Analysis
3.7.4 Future Outlook (2010-2012)
3.8 Granulocyte Colony Stimulating Factor (G-CSF)
3.8.1 Market Size
3.8.2 Key Players and Drugs
3.8.3 Industry Analysis
3.8.4 Future Outlook (2010-2012)
4. Emerging Market Trends
4.1 Biogenerics
4.2 Contract Research Outsourcing
4.3 Contract Manufacturing
4.4 Nanotechnology-enabled Drug Delivery Market
4.5 Healthcare Insurance
4.6 High Approval Rate
5. Growth Inhibitors
5.1 High R&D Cost
5.2 High Price
5.3 High Failure Rates in Phase-3 Clinical Trials
5.4 Insurance Reimbursements
5.5 Lack of Predictability in the Operating Environment
6. Key Players
6.1 Johnson & Johnson
6.2 Biogen Idec Inc.
6.3 Eli Lilly & Company
6.4 Novo Nordisk A/S
6.5 Sanofi-Aventis
6.6 Roche Group
6.7 Amgen Inc.
6.8 Genentech, Inc.
6.9 Merck Serono S.A.
